Vemlidy (tenofovir alafenamide) / Gilead - LARVOL DELTA

CLINICAL OUTCOMES AND MORTALITY PREDICTORS IN HEPATITIS B AND C POSITIVE CHRONIC LIVER DISEASE PATIENTS UNDERGOING MAINTENANCE HEMODIALYSIS IN RESOURCE-LIMITED SETTINGS: A PROSPECTIVE COHORT STUDY (ISN-WCN 2026) - "Direct-acting antivirals (glecaprevir/pibrentasvir or sofosbuvir/velpatasvir) were used for HCV; entecavir or tenofovir alafenamide/disoproxil for HBV with renal dosing. Annual HBV vaccination (89.5% seroprotection) and strict segregation reduced incident infections to zero in segregated units.Conclusion Low albumin and cirrhosis predicted mortality in HBV/HCV-positive CLD patients on MHD. Vaccination, segregation, and timely antiviral therapy were safe, feasible, and associated with improved virologic and survival outcomes in resource-limited dialysis settings."

Clinical • Clinical data • Chronic Kidney Disease • Fibrosis • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Renal Disease

FANCONI SYNDROME INDUCED BY TENOFOVIR ALAFENAMIDE IN A PATIENT WITH CHRONIC HEPATITIS B: A CASE REPORT (ISN-WCN 2026) - "This toxicity can occur early or develop after an extended period. Consequently, regular monitoring of patients on tenofovir—including urinalysis, renal function assessments, and electrolyte balance evaluations—is essential for preventing kidney injury and maintaining renal health."

Case report • Clinical • Cardiovascular • Chronic Kidney Disease • Diabetes • Diabetic Nephropathy • Hepatitis B • Hepatology • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Inflammation • Metabolic Disorders • Musculoskeletal Pain • Nephrology

To Switch or not to Switch: are there any Antiretroviral Strategies to Attenuate Weight Gain in People with HIV? (PubMed, Curr HIV/AIDS Rep) - No abstract available

Journal • Review • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease

Clinical evaluation of lipid profile changes in renal transplant recipients on tenofovir alafenamide for HBV reactivation prophylaxis (ESCMID Global 2026) - No abstract available

Clinical • Hepatitis B • Transplantation

Comparison of the Effects of Tenofovir Alafenamide and Entecavir on Lipid Profiles in Anti-HBc Positive Kidney Transplant Recipients (APASL 2026) - No abstract available

Clinical • Transplantation

Effects of Switching from Tenofovir Alafenamide Fumarate to Tenofovir Disoproxil Fumarate or Entecavir on Lipid Parameters and Atherosclerotic Cardiovascular Disease Risk (APASL 2026) - No abstract available

Atherosclerosis • Cardiovascular

Efficacy and Safety of Tenofovir Alafenamide in the Management of Chronic Hepatitis B in Mongolia (APASL 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Exposure to Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate and the Risk of Hepatocellular Carcinoma (APASL 2026) - No abstract available

Hepatocellular Cancer • Oncology • Solid Tumor

Comparison of Long-term Efficacy and Renal Safety between Entecavir and Tenofovir Alafenamide Fumarate in Treatment-naive Patients with Chronic Hepatitis B (APASL 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Efficacy of Sequential or Combined Tenofovir Alafenamide in Entecavir-Treated CHB Patients with Low-Level Viremia and Its Impact on Lipid Levels (APASL 2026) - No abstract available

Clinical • Hepatitis B

Effectiveness and safety of tenofovir alafenamide for chronic hepatitis B patients with decompensated cirrhosis: a retrospective study in Qinghai province (APASL 2026) - No abstract available

Retrospective data • Fibrosis • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation

Comparative Study of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B in Mongolia (APASL 2026) - No abstract available

Hepatitis B • Hepatology • Infectious Disease • Inflammation

Investigation of the effects of antivirals used in hepatitis B treatment on blood lipid profile: a retrospective real-life data analysis. (PubMed, Minerva Gastroenterol (Torino)) - "TDF causes a decrease in LDL levels, TC and total cholesterol/HDL ratio. However, use of ETV and TAF did not significantly affect the lipid profile. It should not be forgotten that lipid profile changes may cause metabolic health problems in individuals receiving hepatitis B treatment and appropriate treatment should be planned by regular monitoring according to treatment groups."

Journal • Retrospective data • Dyslipidemia • Hepatitis B • Infectious Disease • Inflammation

A 48-week, Randomized Controlled Trial of Doravirine for Individuals with HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391). (PubMed, Clin Infect Dis) - P4 | "In people with HIV and obesity, switching from an INSTI+TAF/FTC regimen to DOR/FTC with either TAF or TDF did not produce clinically meaningful differences in weight change or metabolic health after 48 weeks."

Journal • Genetic Disorders • Human Immunodeficiency Virus • Infectious Disease • Obesity

Fracture risk assessment in patients prescribed pre-exposure prophylaxis for HIV: An audit and comparative evaluation of screening tools. (PubMed, Int J STD AIDS) - "Awareness of fracture risk supports decision making including the need for bone mineral density measurement or use of tenofovir alafenamide-based PrEP...FRAX may be preferable to QFracture due to increased sensitivity and may be more feasible by incorporating fewer variables. Fracture risk assessment in line with national guidelines supports best practice for patient case, and services should therefore audit practice and optimise processes to maximise staff adherence."

Journal • Human Immunodeficiency Virus • Infectious Disease • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Safety and efficacy of long-term tenofovir alafenamide treatment in patients aged 60 years and older with chronic hepatitis B: experience from two phase 3 clinical trials (EASL 2026) - No abstract available

Clinical • P3 data • Hepatitis B • Hepatology • Infectious Disease • Inflammation

Impact of antiviral selection on survival outcomes in hepatitis B-related acute on chronic liver failure: a comparative study of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate from the multicentre APASL ACLF research consortium (EASL 2026) - No abstract available

Clinical • Hepatitis B • Hepatology • Infectious Disease • Inflammation • Liver Failure

Intermittent versus continuous interferon-alpha 2b plus tenofovir alafenamide therapy results in fewer adverse events with similar HBsAg reduction in treatment-naïve HBeAg-negative CHB patients: a multiregional randomized controlled trial in China (EASL 2026) - No abstract available

Adverse events • Clinical • Hepatitis B

Bone Health in People Living with HIV: From Pathophysiology to Practical Management. (PubMed, Infect Chemother) - "Tenofovir alafenamide is associated with improved renal and bone safety profiles. Recent data on integrase inhibitor-based or tenofovir-sparing regimens such as dolutegravir/lamivudine and long-acting cabotegravir plus rilpivirine suggest favorable effects on bon health...Optimizing ART selection to minimize bone toxicity is also an important consideration. As PLWH age, bone health must be integrated into comprehensive HIV care."

Journal • Review • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Renal Disease • Rheumatology

Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate in Lowering the Risk of HCC Development in Patients With CHB. (PubMed, J Gastroenterol Hepatol) - "Compared with TDF, TAF use was associated with an approximately 71% reduction in HCC hazard. Larger cohorts with longer follow-up are warranted to corroborate these observations."

Journal • Diabetes • Hepatitis B • Hepatocellular Cancer • Infectious Disease • Metabolic Disorders • Oncology • Solid Tumor

Real-world use of second-generation integrase strand transfer inhibitors (INSTI) as switch therapy in the prospective ANRS-CO3-AquiVIH-NA cohort. (PubMed, HIV Med) - "In this real-world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle-aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population."

Journal • Real-world evidence • Cardiovascular • Chronic Kidney Disease • Diabetes • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Renal Disease

Development of Biocompatible Nanocarriers for Antiretrovirals Based on Polylactide and Chitosan. (PubMed, AAPS PharmSciTech) - "Herein, we have developed a biocompatible system composed of polylactide and chitosan, loaded with tenofovir alafenamide (TAF) as an antiretroviral drug...Most importantly, the effectiveness of the selected nanoformulations was comparable to that of free TAF (IC50 of 56 nM versus 62-75 nM for NPs), indicating that TAF encapsulation preserved its antiviral effect. The results of this study demonstrate the potential of TAF-loaded NPs and provide a straightforward, effective, and biocompatible strategy for the delivery of anti-HIV drugs."

Journal • Human Immunodeficiency Virus • Infectious Disease

Safety and Effectiveness of Biktarvy® (bictegravir/emtricitabine/tenofovir alafenamide) in Patients with HIV-1 Infection: Interim Report of a Post-Marketing Surveillance Study in Korea. (PubMed, Infect Chemother) - "No serious ADRs were reported. The virological success rate (HIV-1 RNA <50 copies/mL) of Biktarvy treatment at last visit was 96.7%."

Journal • P4 data • Human Immunodeficiency Virus • Infectious Disease

Probiotic Supplementation with BLa80, BL21, and LRa05 Improves Gut Microbiota in Chronic Hepatitis B Patients Receiving Tenofovir Alafenamide: A Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, Probiotics Antimicrob Proteins) - No abstract available

Clinical • Journal • Hepatitis B • Infectious Disease • Inflammation • Metabolic Disorders

Eight-year Results from Two Randomized Phase 3 Trials of Tenofovir Alafenamide for Chronic Hepatitis B Virus Infection in China. (PubMed, J Clin Transl Hepatol) - "No resistance to TAF was detected. Long-term TAF treatment demonstrated durable virologic efficacy, sustained biochemical and serological responses, and favorable renal and bone safety over eight years in Chinese participants with chronic hepatitis B."

Journal • P3 data • Hepatitis B • Infectious Disease • Inflammation